Alapis appoints Lazard for rescue rights and CB advice
Alapis, a Greek pharmaceuticals firm trading at a distressed price, said it plans to raise around Eu98m from a rights issue and potentially Eu300m from convertible bonds, as it reorganises its capital structure. It appointed Lazard & Co. as its financial advisor for the capital raising process. The company will hold an EGM on April 4 to approve the plans.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts